CN110115766A - A kind of compound preparation and preparation method thereof containing flurbiprofen axetil - Google Patents
A kind of compound preparation and preparation method thereof containing flurbiprofen axetil Download PDFInfo
- Publication number
- CN110115766A CN110115766A CN201810115299.3A CN201810115299A CN110115766A CN 110115766 A CN110115766 A CN 110115766A CN 201810115299 A CN201810115299 A CN 201810115299A CN 110115766 A CN110115766 A CN 110115766A
- Authority
- CN
- China
- Prior art keywords
- oil
- compound preparation
- preparation according
- preparation
- proton pump
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of compound preparations containing flurbiprofen axetil, said preparation contains two kinds of active drug active constituents of flurbiprofen axetil and proton pump inhibitor, wherein content of the flurbiprofen axetil in unit dose is 20mg -100mg, content of the proton pump inhibitor in unit dose is 5mg -100mg, invention formulation preferred fat emulsion or fat micro sphere preparation, the blank of flurbiprofen axetil and proton pump inhibitor compound fat emulsion or lipid microspheres injecting drug use is filled up, the exploitation of this preparation so that patient while using Flurbiprofen ester for treating inflammation or pain, effectively prevent and/or treated the gastric injury being induced by it, side effect after making patient medication further decreases.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to a kind of compound preparation containing flurbiprofen axetil, more particularly to
A kind of compound preparation and preparation method thereof being made of flurbiprofen axetil and proton pump inhibitor.
Background technique
Non-steroidal anti-inflammatory drugs (NSAIDs) as it is a kind of have it is anti-inflammatory, ease pain, bring down a fever and reduce platelet adhesion reaction power effect
Drug, be widely used in clinic, but its gastrointestinal side effect is more, clinical manifestation is different, from having no symptom, to showing as
Indigestion, abdominal distension, abdominal pain, ulcer, bleeding, perforation etc., serious person even can threat to life, and the harm of its mucosal lesion
Do not change with dosage form.Therefore, energetically prevent the correlations mucous membrane to the intestines and stomach such as ulcer and bleeding caused by NSAIDs to get over
To get over by clinical attention.
Flurbiprofen be it is a kind of using very extensive nonsteroidal anti-inflammatory drug among clinic, have it is antipyretic, anti-inflammatory and
The effects of analgesic,
It is applied mostly in clinic among to inflammation disease and patient's physiological pain treatment.Preparation among Vehicles Collected from Market
Mostly based on oral, although having certain clinical effectiveness, however, the gastrointestinal tract of patient is easy to cause after taking
Function such as gets muddled at the undesirable reaction, and, to after operative treatment or due to caused by cancer physiology ache
Pain is when being treated, many patients can not oral drugs relieve pain, Flurbiprofen injection is every 5m L's
Containing there is the Flurbiprofen vinegar of 50 m g among emulsion, main application among pain caused by cancer and postoperative pain, with oral medicament
It compares, can reduce the undesirable clinical responses such as stomach lining stimulation, and work compared to medicinal preparation for oral administration faster.
Currently, the trade name Furbiprofen axetil of commercially available florfenicol residues, is with lipid microsphere (also known as Fat Emulsion) system
Agent is carrier, have drug effect is stronger, work more rapidly, the duration it is longer, do not influence the revival etc. in narcosis patient
Advantage, and it is not easy to cause the adverse reactions such as mucosal lesion.Although florfenicol residues substantially reduce on certain Cheng Du
Patient using when there is the probability of gastric injury, but for having the past gastrointestinal tract medical history or gerontal patient, there are stomach and intestine
Gastrointestinal hemorrhage or the risk of perforation are still very big.
Numerous studies confirm that proton pump inhibitor (PPIs) prevents and controls to NSAIDs correlation caused gastrointestinal tract mucosa injury
Treatment is effective, can significantly improve the gastrointestinal symptom of patient, prevention hemorrhage of digestive tract, improve tolerance of the mucous membrane to NSAIDs
Property；In addition, PPIs can also correct the cell growth cycle dynamics upset by NSAIDs to protect stomach lining.Evidence-based medicine EBM
Show that the curative effect of PPIs and safety are superior to Misoprostol and H2 receptor antagonist.Due to the powerful acid suppression of PPIs
Effect, it is extensive in the symptom treatment using stress ulcer or NSAIDs correlation gastric mucosa damage as representative to promote it
It uses.
CN0180616.3 discloses a kind of pharmaceutical composition suitable for oral emulsion preconcentrate form, the composition
Comprising by shape after thering is release property non-steroidal anti-inflammatory drugs, surfactant and oil or semi-solid fat, the composition to contact with gastric juice
At oil-in-water emulsion, meanwhile, the composition can be used in combination with proton pump inhibitor, application method be by above-mentioned composition and
The proton pump inhibitor of enteric coating coating is put into the same medicine box (i.e. capsule)；Patent CN200780022230.6 discloses one
The pharmaceutical composition of kind tegaserod and proton pump inhibitor, including tegaserod and proton pump inhibitor, the composition are used for
It treats or prevents by the drug-induced gastric injury of NSAID；Patent CN201480033480.X draws after disclosing application NSAID drug
The treatment method of the enteropathy risen after for pain or inflammatory patients application NSAID drug, then gives rifaximin and proton pump suppression
Preparation, for preventing or treating by the drug-induced gastric injury of NSAID；Document CN201410317848.7 is prevention Ketoprofen
Injury of gastrointestinal tract develops the compound preparation containing Ketoprofen and Omeprazole, it is characterized in that Ketoprofen is miniature sustained release tablets,
Omeprazole is enteric-coated micro-pill, and then micro chip, pellet are filled in same capsule, are administered simultaneously to patient.
It is drug-induced to disclose treatment NSAID by CN200780022230.6 and CN201480033480.X in above-mentioned document
The treatment method of gastric injury is to cause the treatment after gastric injury for NSAID drug, document CN0180616.3 and
Though CN201410317848.7 is expressed as compound preparation, two different active materials are substantially prepared into different small doses
Type, in filling capsule, due to two kinds of dosage forms of physical presence in capsule, after patient on medication, because of dosage form difference, drug
Release time is uncertain, causes the drug effect time different, for be difficult to play using the drug-induced gastric injury of NSAID it is pre-
How NSAID drug and proton pump inhibitor exploitation are the compound preparation with one dosage type low temperature, so that two kinds of drugs can by anti-effect
To discharge simultaneously, can not only achieve the effect that treat gastric injury, while can effectively prevent gastric injury, pertinent literature does not have also at present
Report.
Summary of the invention
The shortcomings that in order to realize the above object, overcome the prior art, the invention discloses one kind to contain flurbiprofen axetil
Compound preparation, containing there are two types of medicament active compositions in said preparation, one of active pharmaceutical ingredient is flurbiprofen axetil, another
Kind active pharmaceutical ingredient is proton pump inhibitor, and invention formulation effectively prevents or/and controls while treating pain or inflammation
The gastric injury symptom that may cause due to application flurbiprofen axetil is treated.
In the compound preparation of flurbiprofen axetil of the present invention, one of active pharmaceutical ingredient is flurbiprofen axetil,
Content in its preparation in unit dose is 20mg -100mg, preferably 25mg -80mg, further preferably 30mg -
60mg。
In the compound preparation of flurbiprofen axetil of the present invention, wherein another active pharmaceutical ingredient is proton pump inhibition
Agent, proton pump inhibitor (PPI) are the potential inhibition of gastric acid chalk, inhibit H+、 K+ATP enzyme (generates hydrionic in parietal cell
Enzyme involved in final step), term proton pump inhibitor include but is not limited to Omeprazole, Lansoprazole, Pantoprazole,
Rabeprazole, esomeprazole, Iprazole and Lai meter La azoles, including its isomers, enantiomter and tautomer and
Its basic salt, wherein content of the proton pump inhibitor in unit dose formulations is 5mg -100mg, preferably 10mg -80mg.
Proton pump inhibitor generally includes benzimidazole compound, and the proton pump inhibitor that the present invention uses is knownization
It closes object and can be produced by known technique, in certain preferred embodiments, proton pump inhibitor is that the outer of Omeprazole disappears
Revolve compound either Omeprazole (-) enantiomter (that is, esomeprazole), Lansoprazole or Pantoprazole.
In the compound preparation of flurbiprofen axetil of the present invention, wherein proton pump inhibitor is Omeprazole, unit
Content is 10mg -50mg, preferably 12mg- 40mg, further preferred 15mg -35mg in dosage particles.
In the compound preparation of flurbiprofen axetil of the present invention, wherein proton pump inhibitor is Lansoprazole, unit
The content of dosage particles is 10mg -80mg, preferably 15mg -70mg, further preferred 20mg -50mg.
In the compound preparation of flurbiprofen axetil of the present invention, wherein proton pump inhibitor is esomeprazole, list
The content of position dosage particles is 10mg -50mg, preferably 12mg- 40mg, further preferred 15mg -35mg.
In the compound preparation of flurbiprofen axetil of the present invention, wherein proton pump inhibitor is Pantoprazole, unit
Dosage particles content is 10mg -50mg, preferably 12mg- 40mg, further preferred 15mg -35mg.
" unit dose " of the present invention is dosage unit, for the dosage of each individual packets dress, such as solid pharmaceutical preparation
In tablet or capsule, single dose is per a piece of or each capsule, and injection refers to that each Zhi Hanliang is unit dosage.
Flurbiprofen axetil compound preparation of the present invention can be ejection preparation, wherein ejection preparation be fat emulsion,
Lipid microspheres, freeze-dried powder, liquid drugs injection, preferably using fat emulsion and lipid microspheres as the sustained release preparation of carrier.
Fat emulsion or lipid microspheres are existed in the form of emulsion droplet particle, are a kind of oil-in-water lotions, are wrapped in emulsion droplet
Flurbiprofen axetil and proton pump inhibitor active pharmaceutical ingredient are wrapped up in, when emulsion droplet particle arrival lesions position, gradually assembles, is broken
It splits, drug release, greatly improves the bioavilability of drug, and keeping the stabilization of emulsion droplet particle is that drug plays drug effect
Premise, emulsion droplet diameter of particle size are the bases for keeping its stable substantially.But during the preparation process, the type, content of auxiliary material,
Variation of pH etc. can influence the size of emulsion droplet size, easily cause the adverse events such as embolism when partial size is excessive, emulsion droplet is excessive easily
Aggregation, can destroy the balance of grease phase, with the extension of storage event, will cause oil droplet precipitation, it is irreversible to generate demulsification etc.
Change, when emulsion droplet size is too small, cannot effectively wrap up active pharmaceutical ingredient, therefore, it is difficult to reach effective therapeutic effect.This
The average grain diameter of the invention fat emulsion or lipid microspheres is less than 350nm, preferably smaller than 320nm, further preferred 30nm-
300nm, more preferable 50nm -280nm, again preferred 55nm -250nm.
Proton pump inhibitor dissolubility is lower, relatively stable in alkaline environment to light, heat, temperature sensitive, in acidic environment
Middle activation is simultaneously degraded rapidly, but enhances the discomfort of subject if alkalinity is too strong easily to cause injection pain for ejection preparation
The pH of strict control preparation is wanted in reaction, therefore, the present invention, and pH range is 6.0-9.0, further preferred 6.5-8.5.Wherein
PH adjusting agent used is that can be selected from citric acid, citric acid, hydrochloric acid, phosphoric acid, glacial acetic acid, sodium hydroxide (potassium), and buffer reagent can be with
Selected from one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate.
Emulsion droplet particle of the present invention is that oil for injection is formed through emulsifier, above-mentioned molten active material to be added
In liquid, while surfactant is added, the tension of emulsifier surface can be effectively reduced in surfactant, make active pharmaceutical ingredient quilt
Preservation and absorption increase its meltage, and the final load concentration for increasing drug improves the solubility of drug.
Oil for injection is the solvent with dissolution active pharmaceutical ingredient, effectively dissolution pharmaceutical activity, improves its biological utilisation
Degree, oil for injection of the present invention can be soybean oil, sesame oil, safranine caul-fat, castor oil, tea oil, safflower oil, peanut
Oil, olive oil, corn oil and synthesis ethyl oleate, butyl oleate, wherein soybean oil, sweet selected from long chain triglycerides, middle chain
Oily three rouge, Monoolein, glycerol Dan Ya have acid esters, physicochemical property and stability of different types of oil to fat emulsion formulation
All have a great impact, it has been investigated that, long chain triglycerides are capable of providing essential fatty acid and energy, but long-chain glycerol three
Rouge enters mitochondrial metabolism dependent on camitine transporter, and oxidative metabolism speed is slow, and prolonged application can cause immune system function
The toxic side effects such as the adipochrome calmness in obstacle, the accumulation of reticuloendothelial system and liver, spleen, stress or hepatosis suffer from
Person should not apply, and medium chain triglycerides are different from long chain triglycerides, and relative molecular weight is less than long chain triglycerides, and water-soluble
Property it is really 100 times higher than long chain triglycerides, oxidation rapidly, completely, be not easy by the netted intradermal cell of the internal organs such as liver, spleen, lung
It swallows, deposit and endanger immune function, can be reduced a large amount of linoleic balances existed and then maintain fatty acid structure, still
Medium chain triglycerides, which are used alone, cannot provide essential fatty acid, it is also possible to metabolic acidosis and nervous system pair be caused to be made
With, therefore the preferred soybean oil of oil for injection used in the present invention, long chain triglycerides and middle chain are sweet in further preferred soybean oil
The mixture of oily three esters.
W/v of the oil for injection of the present invention in unit dose formulations is 0.1%-20.0%, preferably
0.5%-15.0%, further preferred 0.8%-12.0%, more preferable 0.5% -10%.
Emulsifier can effectively disperse oil for injection and become emulsion droplet particle, effective preservation or absorption active pharmaceutical ingredient,
Emulsifier of the present invention is selected from lecithin, hydroxylated lecithin, soybean lecithin, soybean lecithin, egg yolk lecithin, wherein
Soybean lecithin includes soybean lecithin, hydrogenated soy phosphatidyl choline, high-purity soybean lecithin, Refined Soybean lecithin, yolk
Lecithin includes yellow lecithin, hydrogenated yolk lecithin, the egg yolk lecithin of high-purity and purification egg yolk lecithin.
Emulsifier of the present invention w/v in unit dose formulations is 0.05% -5%, preferably 0.1% -
4%, further preferred 0.2% -3.5%, more preferable 0.5% -3.0%.
Surfactant is the amphipathic compound with surface-active, such as block copolymer.Currently preferred surface
Activating agent is nonionic surfactant, such as poloxamer, cholesterol, NaTDC, polyglycereol palmitinic acid diol ester, second
Sour list glycerol, sorbitol ester, 15- hydroxyl stearic acid macrogol ester (Solutol HS-15) or polyoxyethylene remove water sorb
Sour palmitate.
The weight ratio in unit dose formulations of surfactant of the invention is 0.1%-10%, preferably 0.2%-8%, into one
Walk preferred 0.3%-6.5%, more preferable 0.5% -5.5%.
It, as needed can be in the specific embodiment for preparing fat emulsion or fat micro sphere preparation of the present invention
Add the acceptable pharmaceutic adjuvants such as isotonic regulator, antioxidant or coemulsifier.Wherein isotonic regulator can be
One or more of glucose, glycerol, sodium chloride, sorbierite, xylitol or mannitol, antioxidant can be sulfurous
Sour sodium, sodium hydrogensulfite, sodium pyrosulfite, sodium thiosulfate, ascorbic acid, propylgallate, ascorbyl palmitate,
Butylated hydroxyarisol (BHA), di-t-butyl to add in phenol (BHT), vitamin E, cysteine or methionine one
Kind is several.
Wherein coemulsifier can be glycerol, oleic acid, polyethylene glycol, 1,2- propylene glycol, n-butanol, ethylene glycol, the third two
One or more of alcohol or polyglycerol ester.
Preparation of the invention is orally available, parenteral, part or rectally, they are suitable for the form of every kind of administration route
It gives.Such as they are applied, by injection, perfusion application by injecting sucking, ointment, suppository in the form of a tablet or capsule
Deng application, preferably parenterally, part or rectal administration.
" parenteral " of the present invention and " being parenterally administered " refer to other than enteral and local application
Method of application.Usually by injection system, and include but not limited to it is intravenous, intramuscular, intra-arterial, intracapsular, socket of the eye is interior, intracardiac, skin
In interior, peritonaeum, under transtracheal, subcutaneous, epidermis, under intra-articular, capsule, under arachnoid, intraspinal and breastbone inner injection and concern.
Flurbiprofen axetil compound preparation of the present invention, for treating the inflammation of subject, wherein the inflammation is selected from hair
Heat, arthritis, asthma, bronchitis, dysmenorrhoea, wipe out inflammation, bursal synovitis, skin inflammatory condition, disorder of gastrointestinal tract, angiosis, partially
Headache, kussmaul's disease, thyroiditis, alpastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, severe flesh without
Power, sarcoidosis, nephrotic syndrome, intestinal irritable syndrome, functional dyspepsia FD, Behchet's syndrome, polymyositis, allergy
Swelling and scheming ischemic after disease, conjunctivitis, damage, in certain embodiments, arthritis is selected from rheumatoid arthritis, backbone closes
Save inflammation, gouty arthritis, systemic loupus erythematosus, osteoarthritis and Juvenile arthritis.
Flurbiprofen axetil compound preparation of the present invention, for treating the pain of subject, wherein the pain is selected from warp
Bitterly, pain in the loins, cervicodynia, ostalgia, afterpains, headache, the relevant pain of migraines, toothache, strain, overwork, arthritis, Bones and joints become
Venereal disease, gout, mandatory spondylitis, bursal synovitis, burn, fracture, immune and autoimmunity, the neoplastic of cell turn
Shifting property tumour growth, pain caused by cancer and surgery and dentistry postoperative pain.
The compound preparation of flurbiprofen axetil of the present invention be mainly used for treat rheumatoid arthritis, osteoarthritis,
Mandatory rachitis, trauma pain, pain caused by cancer and surgery and dentistry postoperative pain.
Flurbiprofen axetil compound preparation of the present invention, suitable for there is the patient of the past injury of gastrointestinal tract, wherein stomach is damaged
Wound includes inflammatory bowel disease (IBD) and functional bowel disorder disease (FBD), including indigestion and to the gastroesophageal reflux of FBD and more
The splanchnodynia of kind form.In certain embodiments, gastric injury be by be it is drug-induced by NSAID, in specific embodiment, this
The invention pain or inflammation are selected from mucosa injury, stomach muscle dysfunction, gastritis, gastric erosion, gastric ulcer or gastric damage.
It is of the present invention containing flurbiprofen axetil compound preparation be Fat Emulsion injection, as long as preparation is suitable as infusing
Penetrate agent, for the said preparation comprising Fat Emulsion form there is no limit, specific example include be packed into container (such as ampoule, XiLin,
Prefilled syringe) in preparation.
Present invention firstly discloses Fat Emulsion or fat micro sphere preparation containing flurbiprofen axetil and proton pump inhibitor compound,
Said preparation treats inflammation or pain, can effectively prevent and/or treat by the drug-induced gastric injury of NSAID, especially for having
The past gastric injury medical history or gerontal patient, this preparation can effectively prevent gastric injury, keep patient medication safer, can be greatly reduced
The generation of side reaction；Its deuterzooid compound preparation gives patient's a drug and can reach treatment inflammation and prevent gastric injury
Double action does not need patient and distinguishes medication, and patient medication is more convenient, improves the compliance of patient medication；Finally, this hair
Compound preparation stable dosage forms, can long term storage, the clinical drug safety greatly met.
Figure of description
Fig. 1 zoopery effect picture.
Specific embodiment
1 flurbiprofen axetil of embodiment and Omeprazole Fat Emulsion
| Composition | Sample 1 | Sample 2 |
| Flurbiprofen axetil | 5.0g | 5.0g |
| Omeprazole | 1.0g | 2.0g |
| Soybean oil | 17.5g | 17.5g |
| Egg yolk lecithin | 7.5g | 7.5g |
| Solutol HS-15 | 15g | 15g |
| Vitamin E | 3.0g | 3.0g |
| Glycerol | 12g | 12g |
| Water | Add water to 500ml | Add water to 500ml |
| pH | 8.1 | 8.1 |
Preparation method: the soybean oil of recipe quantity and egg yolk lecithin are uniformly mixed, and are adjusted using citric acid and sodium dihydrogen phosphate
PH is added active pharmaceutical ingredient Flurbiprofen and Omeprazole, is uniformly dispersed；Be added recipe quantity Solutol HS-15,
It is uniformly mixed；The glycerol of recipe quantity is added, adding suitable water to liquor capacity is 500mL, and mixing and emulsifying is equal using high pressure
The shearing of matter machine；Acquired solution is filtered, encapsulating, sterilizing to get.
2 flurbiprofen axetil of embodiment and Lansoprazole Fat Emulsion
| Composition | Content |
| Flurbiprofen axetil | 5.0g |
| Lansoprazole | 3.0g |
| Soybean oil | 20g |
| Egg yolk lecithin | 10g |
| Poloxamer | 12g |
| Vitamin E | 3.0g |
| Glycerol | 12g |
| Water | Add water to 500ml |
| Ph | 7.6 |
Preparation method: as described in Example 1.
Embodiment 3 sterilizes front and back droplet measurement to sample prepared by embodiment 1,2
Use sample prepared by Laser Scattering Particle instrument (model: Zetasizer, producer: Malvern) detection embodiment 1-9
Droplet measurement before and after sterilizing, as a result as shown in table 1 below:
Table 1
As seen from the results in Table 1, emulsion droplet size is relatively stable before and after the present invention does the fat emulsion sterilizing prepared, to further protect
The stability of the preparation of card ensure that the drug safety of patient.
Embodiment 4
The selection of oil for injection in 4.1 prescriptions
It is as follows that the influence of injecting drug use type and dosage to preparation, prescription in prescription have been investigated in this experiment:
Above-mentioned sample is sterilized front and back droplet measurement, and the results are shown in Table 2:
Table 2
The screening of 4.2 emulsifiers
Above-mentioned sample is sterilized front and back droplet measurement, and the results are shown in Table 3:
Table 3
The screening of 4.3 surfactants
Above-mentioned sample is sterilized front and back droplet measurement, and the results are shown in Table 4:
Table 4
4.4 investigation for pH in preparation
Above-mentioned sample is sterilized front and back droplet measurement, and the results are shown in Table 5:
It can be seen from the above result that constantly studying by inventor, fat emulsion formulation stability disclosed in this invention is strong, energy
Sufficiently meet clinical demand.
5 zoopery of embodiment
The male Wistar rat (Beijing Vital River Experimental Animals Technology Co., Ltd.) of 8 week old is bought, weight is about 240g-
260g makes its water of freely ingesting, and after pre- raising 7 days, with 10 for one group, total 5 groups are tested, and is divided into 1 control group
With 4 experimental groups, administration mode is described in table 2 below, fasting 24 hours before testing, before prohibiting water 1 hour.
Table 2
From fasting when testing the previous day 11, said medicine is given in intravenous injection on the day of test, uses carbon dioxide after 5 hours
Gas is euthanized and wins out stomach.Duodenum is ligatured, neutral formalin 6mL is injected from esophagus, in neutral Fu Er
It is placed 30 minutes in Malin's solution.It is cut along greater curvature shape, after gently being cleaned with physiological saline, in stereomicroscope
Under see whether bleeding occur.The area of bleeding, the i.e. area of ulcer are measured using 0.5mm × 0.5mm as unit, as a result such as Fig. 1
It is shown.
By the results show that joined the flurbiprofen axetil fat emulsion formulation of proton pump inhibitor, ulcer area significantly drops
Low, to illustrate, compound preparation disclosed in this invention can effectively prevent and/or treat the effect of gastric injury.
Claims (12)
1. a kind of compound preparation containing flurbiprofen axetil, said preparation is to contain the two kinds of work of flurbiprofen axetil and proton pump inhibitor
The ejection preparation of property drug ingedient；
Wherein also contain
The oil for injection that w/v in unit dose formulations is 0.1%-20.0%,
The emulsifier that w/v is 0.05% -5% in unit dose formulations,
Weight ratio is the surfactant of 0.1%-10% in unit dose formulations；
Wherein proton pump inhibitor can be selected from Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole, esomeprazole, Chinese mugwort
Pula azoles or Lai meter La azoles.
2. compound preparation according to claim 1, it is characterised in that content of the flurbiprofen axetil in unit dose
For 20mg -100mg, content of the proton pump inhibitor in unit dose formulations is 5mg -100mg.
3. compound preparation according to claim 1, it is characterised in that the oil for injection is selected from soybean oil, sesame oil, hiding
Safflower oil, castor oil, tea oil, safflower oil, peanut oil, olive oil, corn oil, synthesis ethyl oleate or butyl oleate.
4. compound preparation according to claim 1, it is characterised in that the emulsifier is selected from lecithin, hydroxyl lecithin
Rouge, soybean lecithin, soybean lecithin or egg yolk lecithin.
5. compound preparation according to claim 1, it is characterised in that the surfactant is non-ionic surface active
Agent.
6. compound preparation according to claim 1, it is characterised in that the proton pump inhibitor be Omeprazole or
Lansoprazole.
7. compound preparation according to claim 1, it is characterised in that the ejection preparation be fat emulsion, lipid microspheres,
Freeze-dried powder, liquid drugs injection.
8. compound preparation according to claim 4, it is characterised in that the average grain diameter of the fat emulsion or lipid microspheres
Less than 350nm.
9. compound preparation according to claim 1, it is characterised in that its pH of the preparation is 6.0-9.0.
10. compound preparation according to claim 1, it is characterised in that said preparation is orally available, parenteral, part or rectum are given
Medicine, preferably parenterally, part or rectal administration.
11. compound preparation according to claim 1, it is characterised in that said preparation is applied by injection system.
12. compound preparation according to claim 1, it is characterised in that invention formulation is for treating pain or inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810115299.3A CN110115766B (en) | 2018-02-06 | 2018-02-06 | Compound preparation containing flurbiprofen axetil and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810115299.3A CN110115766B (en) | 2018-02-06 | 2018-02-06 | Compound preparation containing flurbiprofen axetil and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110115766A true CN110115766A (en) | 2019-08-13 |
| CN110115766B CN110115766B (en) | 2022-05-20 |
Family
ID=67519610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810115299.3A Active CN110115766B (en) | 2018-02-06 | 2018-02-06 | Compound preparation containing flurbiprofen axetil and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110115766B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070154542A1 (en) * | 2005-12-30 | 2007-07-05 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| CN106109412A (en) * | 2016-07-27 | 2016-11-16 | 武汉科福新药有限责任公司 | Flurbiprofen axetil lipid microsphere injection and preparation method thereof |
| CN107224585A (en) * | 2016-03-25 | 2017-10-03 | 南京优科制药有限公司 | A kind of composition comprising NSAIDs and proton pump inhibitor |
-
2018
- 2018-02-06 CN CN201810115299.3A patent/CN110115766B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070154542A1 (en) * | 2005-12-30 | 2007-07-05 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| CN107224585A (en) * | 2016-03-25 | 2017-10-03 | 南京优科制药有限公司 | A kind of composition comprising NSAIDs and proton pump inhibitor |
| CN106109412A (en) * | 2016-07-27 | 2016-11-16 | 武汉科福新药有限责任公司 | Flurbiprofen axetil lipid microsphere injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110115766B (en) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Enhancing stability and anti-inflammatory properties of curcumin in ulcerative colitis therapy using liposomes mediated colon-specific drug delivery system | |
| AU2018100110A4 (en) | Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto | |
| EP3131541A1 (en) | Ion channel activators and methods of use | |
| KR102162901B1 (en) | Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same | |
| JP6276756B2 (en) | 1,1-dimethylethyl [(1S) -1-{[(2S, 4R) -4- (7-chloro-4methoxyisoquinolin-1-yloxy) -2-({(1R, 2S) -1- [ Solubilized capsule formulation of (cyclopropylsulfonyl) carbamoyl] -2-ethenylcyclopropyl} carbamoyl) pyrrolidin-1-yl] carbonyl} -2,2-dimethylpropyl] carbamate | |
| AU2015236283B2 (en) | Compositions for the treatment of autodigestion | |
| TW201521719A (en) | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same | |
| CA2690488A1 (en) | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof | |
| US20230398132A1 (en) | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | |
| Tehseen et al. | Design and characterization of twice daily mini-tablets formulation of pregabalin | |
| JP2017186346A (en) | Non-intravenous dosage form comprising solid formulation of liquid biologically active component and uses thereof | |
| US20150342882A1 (en) | Methods of treatment using cadotril compositions | |
| KR101050015B1 (en) | Pharmaceutical Compositions of Lobules Extracts Using Gastric Retention Drug Delivery System and Sustained-release Oral Preparations | |
| JP2005504788A (en) | Novel self-emulsifying drug delivery system | |
| CN103505414B (en) | Butylphthalide nasal drop and preparation method thereof | |
| US20110028567A1 (en) | Smooth muscle contraction inhibitors | |
| JP7325753B2 (en) | Ulcerative colitis treatment capsules | |
| CN110115766A (en) | A kind of compound preparation and preparation method thereof containing flurbiprofen axetil | |
| JP3103513B2 (en) | Shark cartilage oral ingestion preparation | |
| AU2005275594A1 (en) | Gastric therapies and compositions therefor | |
| JP4842802B2 (en) | Oral administration vector | |
| Hsieh et al. | Nanostructured lipid carriers containing a high percentage of a Pluronic copolymer increase the biodistribution of novel PDE4 inhibitors for the treatment of traumatic hemorrhage | |
| RU2133122C1 (en) | Composition exhibiting property for biological membrane repairing | |
| RU2818017C2 (en) | Method for preparing oral form of substance containing insulin | |
| WO2023200363A1 (en) | Method for producing an oral form of an insulin-containing substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |